Crossmark

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database

Crossref DOI link: https://doi.org/10.1007/s00262-024-03858-4

Published Online: 2024-11-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Zhaohui

Zhou, Zixiang

Zhang, Nan

Tian, Binhe

Chen, Xiangqi

Zhao, Haitao

Wang, Hanping
Funding

Funding for this research was provided by:

National High Level Hospital Clinical Research Funding (2022-PUMCH-A-131)
License Information

Text and Data Mining valid from 2024-11-15

Version of Record valid from 2024-11-15
More Information

Article History

Received: 10 March 2024

Accepted: 9 October 2024

First Online: 15 November 2024

Declarations

:

: There are no conflicts of interest to declare.

: Since the FAERS database is accessible to the public and patient records are anonymized and de-identified, ethical clearance and informed consent are not required for this study.

Document is current

Any future updates will be listed below